SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Hold" from Analysts

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) has been given a consensus rating of "Hold" by the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $52.57.

A number of analysts recently issued reports on the company. Guggenheim reissued a "neutral" rating and set a $47.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday, May 12th. Cowen downgraded SpringWorks Therapeutics to a "hold" rating in a research report on Tuesday, April 29th. Barclays restated an "equal weight" rating and set a $47.00 target price (down previously from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. TD Cowen reiterated a "hold" rating and issued a $47.00 price objective (down previously from $66.00) on shares of SpringWorks Therapeutics in a research note on Tuesday, April 29th. Finally, Wedbush reiterated a "neutral" rating and issued a $47.00 price objective (down previously from $81.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th.

Institutional Trading of SpringWorks Therapeutics

Large investors have recently made changes to their positions in the stock. Huntington National Bank boosted its stake in shares of SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock worth $25,000 after acquiring an additional 192 shares in the last quarter. AlphaQuest LLC lifted its position in shares of SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock worth $36,000 after purchasing an additional 414 shares during the last quarter. Twin Tree Management LP acquired a new position in shares of SpringWorks Therapeutics during the 1st quarter worth about $37,000. Venturi Wealth Management LLC acquired a new position in shares of SpringWorks Therapeutics during the 4th quarter worth about $45,000. Finally, State of Wyoming lifted its position in shares of SpringWorks Therapeutics by 39.5% during the 4th quarter. State of Wyoming now owns 1,530 shares of the company's stock worth $55,000 after purchasing an additional 433 shares during the last quarter.

SpringWorks Therapeutics Price Performance

Shares of SWTX remained flat at $46.87 during mid-day trading on Tuesday. 4,186,446 shares of the stock traded hands, compared to its average volume of 2,400,761. SpringWorks Therapeutics has a 12-month low of $28.21 and a 12-month high of $62.00. The firm's fifty day simple moving average is $44.28 and its 200 day simple moving average is $43.87. The company has a market capitalization of $3.53 billion, a P/E ratio of -13.47 and a beta of 0.70.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). The company had revenue of $49.09 million during the quarter, compared to analyst estimates of $64.19 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. On average, sell-side analysts predict that SpringWorks Therapeutics will post -2.05 earnings per share for the current fiscal year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.